However, in the current study, sorafenib showed neither selectivity against the proliferation of HCC cell lines with the activated FGF pathway nor downregulation of p‐Erk1/2 in xenograft tumors (Figs 1 and 3), suggesting that sorafenib may not affect FGF signaling pathways in these preclinical HCC models. Here, MAPK3 is linked to hepatocellular carcinoma.